MV140 Vaccine Helped People Remain UTI-Free For Years

New Delhi: Urinary Tract Infection (UTI) is a common bacterial infection said to be experienced by half of all women and one in five men. However, a study has shown that more than 50 per cent of people remained UTI-free for up to nine years who received the oral spray-based vaccine ‘MV140’.

According to the study published in the journal European Association of Urology, the MV140 vaccine is a potential alternative to antibiotic treatments. About 54 per cent of study participants remained UTI-free for nine years after the vaccine, with no notable side effects reported.

“Recurrent infections, needing short-term antibiotic treatment, develop in between 20 to 30 per cent of cases,” the study mentioned. This study, conducted by specialists at the UK’s Royal Berkshire Hospital, examined the safety and efficacy of the MV140 vaccine in 89 patients.

“Nine years after first receiving this new UTI vaccine, around half of participants remained infection-free. Overall, this vaccine is safe in the long term and our participants reported having fewer UTIs that were less severe,” said Dr Bob Yang, Consultant Urologist at the Royal Berkshire NHS Foundation Trust, who co-led the study.

MV140 vaccine was administered with two sprays of a pineapple-flavoured suspension under the tongue every day for three months in patients.

Developed by the Spain-based pharmaceutical company Immunotek, MV140 contains four bacterial species in a suspension with water. It is available off-license in 26 countries. In the research, 48 participants remained entirely infection-free during the nine-year follow-up.

The average infection-free period across the cohort was 54.7 months (four and a half years) – 56.7 months for women and 44.3 months, one year less, for men. 40 per cent of participants reported having repeat doses of the vaccine after one or two years, the study noted.

“This follow-up study reveals encouraging data about the long-term safety and effectiveness of the MV140 vaccine,” said Gernot Bonkat, Professor at the Alta Uro Medical Centre for Urology in Switzerland.

Related Posts

  • Pharma
  • January 21, 2025
  • 27 views
Glenmark Pharma share rises 2% as unit launches blood clotting drug

Glenmark Pharmaceuticals share price:Pharmaceutical major Glenmark Pharmaceuticals shares rose up to 2.23 per cent to hit an intraday high of Rs 1,537.90 per share on Tuesday, January 21, 2025. The…

  • Pharma
  • January 21, 2025
  • 48 views
Fire breaks out at pharmaceutical company in Andhra Pradesh, no casualty

A fire broke out at a pharmaceutical company in Andhra Pradesh’s Parawada, early Tuesday (January 21) morning. The flames, which erupted in the effluent treatment plant around 6.30 am, were…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Glenmark Pharma share rises 2% as unit launches blood clotting drug

Glenmark Pharma share rises 2% as unit launches blood clotting drug

Fire breaks out at pharmaceutical company in Andhra Pradesh, no casualty

Fire breaks out at pharmaceutical company in Andhra Pradesh, no casualty

Pharma body to cap prices of cigarette substitutes, seeks data

Pharma body to cap prices of cigarette substitutes, seeks data

Budget 2025: Pharma industry lays out a plan to curb Chinese dependence

Budget 2025: Pharma industry lays out a plan to curb Chinese dependence

Aurobindo Pharma Ltd rises for third straight session

Aurobindo Pharma Ltd rises for third straight session

Pharmaceutical firm in Baddi raided again

Pharmaceutical firm in Baddi raided again